Clinical trial · Interventional
Efficacy and Safety of 500mg of Fulvestrant
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
NCT00585507CI-TRIAL-00112340active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fulvestrant | Drug | Fulvestrant | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- single
- description
- fulvestrant 500mg
- interventionNames
- Drug: Fulvestrant
Primary outcomes (1)
- measure
- To assess the clinical benefit rate for subjects receiving this dose and schedule of fulvestrant.
Secondary outcomes (3)
- measure
- Overall objective response rate, time to response, duration of response, duration of clinical benefit, and time to progression.
- measure
- Assessment of adverse events
- timeFrame
- 4 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female * 18 years of age or older * Histologically confirmed adenocarcinoma of the breast progressing local-regional or metastatic disease that is not considered amenable to curative treatment * Evidence of hormone sensitivity of primary or secondary tumor tissue * Postmenopausal as defined by criteria listed in protocol * May have had adjuvant endocrine therapy if discontinued at least 12 months prior to inclusion. Subjects who have had minimal exposure to adjuvant or first line metastatic endocrine treatment during the 12 months prior to study enrollment can be eligible with overall PI and sponsor permission * Prior trastuzumab and biologic therapy is allowed, but must be discontinued more than 2 weeks prior to inclusion * Presence of measurable or evaluable, nonmeasurable, disease. Any x-rays and scans for assessment of measurable disease must be performed with 28 days prior to registration * Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2 Exclusion Criteria: * Presence of life-threatening metastatic disease * Endocrine therapy the advanced disease setting * Systemic chemotherapy, whether as adjuvant therapy or for advanced disease, within previous 4 weeks * Trastuzumab or biologic therapy within previous 2 weeks * Extensive radiation therapy within the last 2 weeks * Prior adjuvant or neoadjuvant treatment with fulvestrant is not allowed * Concomitant anticancer treatments * Chronic bisphosphonates for hypercalcemia or prevention of bone metastases * Subjects receiving long-term anticoagulant therapy with warfarin * Estrogen replacement therapy within 6 months of trial entry * Previous or current systems malignancy within the past 3 years * Treatment with non approved or investigational drug within 2 weeks before study entry * Any evidence of severe or uncontrolled systemic disease * History of bleeding diathesis * Any severe concomitant condition which makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.